These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8962241)

  • 1. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
    Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
    [No Abstract]   [Full Text] [Related]  

  • 2. Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
    Neuhaus P; Bechstein WO; Blumhardt G; Steffen R; Keck H; Lemmens P; Langrehr JM; Schlag H
    Transplant Proc; 1993 Apr; 25(2):1940-1. PubMed ID: 8470234
    [No Abstract]   [Full Text] [Related]  

  • 3. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy.
    Neuhaus B; Keck H; Bechstein WO; Blumhardt G; Langrehr JM; Wiens M; Lemmens HP; Lohmann R; Schlag H; Thalmann U
    Transplant Proc; 1993 Feb; 25(1 Pt 1):587-9. PubMed ID: 8438426
    [No Abstract]   [Full Text] [Related]  

  • 4. Quadruple-drug therapy with antithymocyte globulin in the early postoperative period after liver transplantation.
    Schattenfroh N; Lange D; Bechstein WO; Blumhardt G; Lohmann R; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1968-9. PubMed ID: 8470245
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract]   [Full Text] [Related]  

  • 7. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
    Lohmann R; Langrehr JM; Klupp J; Neumann U; Guckelberger O; Müller AR; Nüssler NC; Jonas S; Lang M; Settmacher U; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1999; 31(1-2):380. PubMed ID: 10083151
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithymocyte globulin or interleukin 2 receptor antibody for immunosuppressive induction therapy after orthotopic liver transplantation: a follow-up study.
    Keck H; Langrehr JM; Knoop M; Lohmann R; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2701. PubMed ID: 8356721
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract]   [Full Text] [Related]  

  • 10. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
    Glanemann M; Langrehr JM; Raakow R; Guckelberger O; Lohmann R; Klupp J; Lobeck H; Schlag H; Keck H; Bechstein WO; Settmacher U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
    Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
    Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of antilymphocyte induction therapy in liver transplantation.
    Wall WJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
    Schulz T; Kapischke M; Busing M
    Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of primary immunosuppression on the incidence of infectious complications after orthotopic liver transplantation.
    Lohmann R; Langrehr JM; Raakow R; Jonas S; Klupp J; Steinmüller T; Neuhaus R; Neuhaus P
    Transplant Proc; 2000 Nov; 32(7):2229-30. PubMed ID: 11120145
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
    Lemmens HP; Langrehr JM; Bechstein WO; Blumhardt G; Keck H; Lüsebrink R; Knoop M; Lohmann R; Tullius S; Lobeck H
    Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized trial comparing anti-interleukin-2 receptor antibody and placebo for immunosuppressive therapy after OLT.
    Langrehr JM; Glanemann M; Schneller A; Neumann U; Guckelberger O; Lohmann R; Klupp J; Jonas S; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1998 Jun; 30(4):1445-6. PubMed ID: 9636586
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation.
    Langrehr JM; Schneller A; Guckelberger O; Lohmann R; Neumann U; Jonas S; Klupp J; Settmacher U; Knoop M; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1998 Jun; 30(4):1439-40. PubMed ID: 9636583
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis.
    Langrehr JM; Lemmens HP; Keck H; Lohmann R; Knoop M; Neumann U; Müller AR; Platz KP; Kling N; Hopf U
    Transplant Proc; 1995 Feb; 27(1):1215-6. PubMed ID: 7533373
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
    Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
    Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.